Yes, and still take it

Yes, it helps me and will it help you nobody knows until you try it.

With me a takes a few days but with others it might take awhile depending on
the type and severity of symptoms.

Really dude, take one pill at one meal and take another at another meal to
stretch the dose.

Sometimes joint pain or aches and pains. Do not take on an empty stomach
otherwise GiI symtoms.

DO not take with antibiotics as it can inhibit absorption of some of them.
Do not take with Digoxin.

Personally no.

Unlike most other supplements, it at least has published scientific
data:

J Urol. 2001 Nov;166(5):1738-41.

Correlation of beta-endorphin and prostaglandin E2 levels in prostatic
fluid of patients with chronic prostatitis with diagnosis and
treatment response.

Shahed AR, Shoskes DA.

Harbor-University of California-Los Angeles Medical Center, Torrance,
California, USA.

PURPOSE: The chronic pelvic pain syndrome is a clinically defined
symptom complex of unclear etiology. We have noted increased oxidative
stress in the prostatic fluid of these patients, implying an active
inflammatory response. Immune cells can produce the natural opioid
beta-endorphin at the site of injury, which may modulate pain. We
measured beta-endorphin and the inflammatory marker prostaglandin E2
in the expressed prostatic secretions of men with prostatitis, and
correlated the results with symptoms. MATERIALS AND METHODS: Expressed
prostatic secretions samples from 70 patients and 8 asymptomatic
controls were collected and frozen. beta-Endorphin and prostaglandin
E2 were measured by enzyme-linked immunosorbent assay. Results were
stratified according to prostatitis category and compared in
individuals before and after therapy. RESULTS: In symptomatic patients
beta-endorphin and prostaglandin E2 were not significantly different
in categories II, IIIa and IIIb expressed prostatic secretions but
they were higher than in controls. The mean beta-endorphin level plus
or minus standard error of mean in symptomatic patients was
significantly higher (23.8 +/- 11 ng./ml. versus 8.7 +/- 4.7, p =
0.0001) and mean prostaglandin E2 was lower (6.01 +/- 2.9 ng./ml.
versus 3.01 +/- 2.9, p = 0.001) after successful therapy with
antibiotics or antioxidant phytotherapy, Prosta-Q (Farr Laboratories,
Santa Clarita, California). CONCLUSIONS: We observed a correlation of
higher prostaglandin E2 and lower beta-endorphin in symptomatic men
with chronic prostatitis. Increased oxidative stress and inflammation
may induce prostaglandin E2 production that would inhibit
beta-endorphin release. Treatment with therapeutic agents that
decrease oxidative stress, such as antibiotics and antioxidant
phytotherapy, may function at least partially by increasing
beta-endorphin and decreasing prostaglandin E2.

2: J Androl. 2000 Sep-Oct;21(5):669-75.
 
Oxidative stress in prostatic fluid of patients with chronic pelvic
pain syndrome: correlation with gram positive bacterial growth and
treatment response.

Shahed AR, Shoskes DA.

Division of Urology, Harbor-UCLA Medical Center, Torrance, California,
USA.

The etiology of chronic pelvic pain syndrome (CPPS)/chronic
prostatitis category III remains unknown. Whereas a subset of men
respond to antimicrobial therapy, gram positive bacteria isolated from
expressed prostatic secretions (EPS) are often considered to be
commensal rather than pathogenic. We wished to study oxidative stress
as a marker of tissue injury and response in EPS of men with CPPS to
determine whether infection with gram positive bacteria is associated
with increased oxidative stress. A total of 300 EPS specimens from 100
men with CPPS were collected for microscopy, culture, and biochemical
and molecular assays. Oxidant injury was measured by 8-isoprostane
F2alpha (IsoP) levels and total antioxidant capacity as Trolox
equivalents. Total RNA from EPS was used for gene expression of heme
oxygenase-1 (HO-1) and granzyme B. The only bacteria found in EPS were
gram positive. For our analysis, these men were classified as having
chronic bacterial prostatitis (category II). IsoP levels (pg/mL) were
highest in men with category II prostatitis (7315 +/- 1428) followed
by nonbacterial prostatitis (category IIIa, 2043 +/- 561),
prostatodynia (category IIIb, 319 +/- 81), and asymptomatic controls
(298 +/- 99). IsoP levels decreased significantly after successful
treatment with antibiotics or an antioxidant supplement (Prosta-Q).
Antioxidant capacity was detected in 11 out of 18, 4 out of 16, and 1
out of 16 men tested with category II, IIIa, and IIIb prostatitis,
respectively. No correlation was observed between IsoP levels and the
number of white blood cells in EPS. HO-1 and granzyme B expression was
highest in men with category II prostatitis than in men with either
category III prostatitis or asymptomatic controls. On the basis of
elevated oxidative stress, clinical response to antibiotics, and
post-treatment reduction in oxidative stress, we conclude that gram
positive bacteria in some men with CPPS may be pathogens. It is
speculated that oxidative stress may be a key pathway in some men with
CPPS that can be targeted with antioxidant therapy.

3: Urology. 1999 Dec;54(6):960-3.

 
Quercetin in men with category III chronic prostatitis: a preliminary
prospective, double-blind, placebo-controlled trial.

Shoskes DA, Zeitlin SI, Shahed A, Rajfer J.

Institute for Male Urology, Encino, California, USA.

OBJECTIVES: The National Institutes of Health (NIH) category III
chronic prostatitis syndromes (nonbacterial chronic prostatitis and
prostatodynia) are common disorders with few effective therapies.
Bioflavonoids have recently been shown in an open-label study to
improve the symptoms of these disorders in a significant proportion of
men. The aim of this study was to confirm these findings in a
prospective randomized, double-blind, placebo-controlled trial.
METHODS: Thirty men with category IIIa and IIIb chronic pelvic pain
syndrome were randomized in a double-blind fashion to receive either
placebo or the bioflavonoid quercetin 500 mg twice daily for 1 month.
The NIH chronic prostatitis symptom score was used to grade symptoms
and the quality-of-life impact at the start and conclusion of the
study. In a follow-up unblind, open-label study, 17 additional men
received 1 month of a supplement containing quercetin, as well as
bromelain and papain (Prosta-O), which enhance bioflavonoid
absorption. RESULTS: Two patients in the placebo group refused to
complete the study because of worsening symptoms, leaving 13 placebo
and 15 bioflavonoid patients for evaluation in the blind study. Both
the quercetin and placebo groups were similar in age, symptom
duration, and initial symptom score. Patients taking placebo had a
mean improvement in NIH symptom score from 20.2 to 18.8 (not
significant), while those taking the bioflavonoid had a mean
improvement from 21.0 to 13.1 (P = 0.003). Twenty percent of patients
taking placebo and 67% of patients taking the bioflavonoid had an
improvement of symptoms of at least 25%. In the 17 patients who
received Prosta-Q in the open-label study, 82% had at least a 25%
improvement in symptom score. CONCLUSIONS: Therapy with the
bioflavonoid quercetin is well tolerated and provides significant
symptomatic improvement in most men with chronic pelvic pain syndrome.

Prosta-q's website is pretty meager for info but there is a summary
here:

www.dshoskes.com/prostaq.html

It can't hurt. But u should see a good URO also.

I find a good brand of quercitan from the local store works just as good for
me.

I use Solgar brand - but there are others.

It is only $8 compared to ProstaQ's $40